Pilot Study on the Effect of Linaclotide in Patients With Chronic Constipation

被引:83
作者
Johnston, Jeffrey M. [1 ]
Kurtz, Caroline B. [1 ]
Drossman, Douglas A. [2 ]
Lembo, Anthony J. [3 ]
Jeglinski, Brenda I. [1 ]
MacDougall, James E. [1 ]
Antonelli, Stephen M. [1 ]
Currie, Mark G. [1 ]
机构
[1] Ironwood Pharmaceut Inc, Cambridge, MA USA
[2] Univ N Carolina, Sch Med, Div Gastroenterol & Hepatol, Chapel Hill, NC USA
[3] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA
关键词
UNITED-STATES; TRANSIT; MD-1100; GUANYLIN; TOLERABILITY; UROGUANYLIN; EXPOSURE; PEPTIDE; SAFETY;
D O I
10.1038/ajg.2008.59
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVES: Chronic constipation is a common gastrointestinal disorder with limited treatment options. Oral administration of linaclotide, a novel peptide agonist of guanylate cyclase-C receptors, has been shown in animal studies to stimulate intestinal fluid secretion and transit. In Phase 1 studies in healthy human volunteers, linaclotide was well-tolerated, increased bowel movement frequency, and loosened stool consistency. METHODS: This randomized, double-blind, placebo-controlled pilot study evaluated the safety, tolerability, and exploratory efficacy of oral linaclotide in 42 patients with chronic constipation. Patients were randomized to linaclotide (100, 300, or 1,000 mu g) or placebo once daily for 2 weeks. Bowel habits (stool frequency, consistency, straining, completeness of evacuation) and degree of abdominal discomfort were monitored daily using an interactive voice response system. Patient-reported outcomes of severity of constipation and overall relief were evaluated weekly. RESULTS: Linaclotide treatment produced dose-dependent increases from the pretreatment baseline values in weekly complete spontaneous bowel movement frequency (range: 2.2-3.2), stool consistency scores (range: 1.1-2.6, 7-point scale), and straining scores (range: 0.4-1.5, 7-point scale); corresponding placebo increases were 1.3, 0.4, 0.4, respectively. Clinical improvements were also demonstrated in abdominal discomfort, severity of constipation, and overall relief. Compared to placebo, linaclotide 100 mu g/day significantly increased spontaneous bowel movement frequency, and linaclotide 1,000 mu g/day significantly improved stool consistency (P < 0.05). Adverse events were primarily gastrointestinal, with diarrhea being the most common. CONCLUSIONS: In this pilot study, linaclotide treatment improved bowel habits and symptoms of patients with chronic constipation. Further randomized controlled trials are warranted.
引用
收藏
页码:125 / 132
页数:8
相关论文
共 29 条
[1]   Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome [J].
Andresen, Viola ;
Camilleri, Michael ;
Busciglio, Irene A. ;
Grudell, April ;
Burton, Duane ;
Mckinzie, Sanna ;
Foxx-Orenstein, Amy ;
Kurtz, Caroline B. ;
Sharma, Vineeta ;
Johnston, Jeffrey M. ;
Currie, Mark G. ;
Zinsmeister, Alan R. .
GASTROENTEROLOGY, 2007, 133 (03) :761-768
[2]  
[Anonymous], 2006, Common Terminology Criteria for Adverse Events Internet
[3]  
Bottoli I, 2006, GASTROENTEROLOGY, V130, pA321
[4]  
Bryant AP, 2005, GASTROENTEROLOGY, V128, pA464
[5]   Antinociceptive actions of MD-1100, a novel therapeutic agent for c-IBS, in animal models of visceral pain [J].
Bueno, L ;
Beaufrand, C ;
Mahajan-Miklos, S ;
Bryant, AP ;
Currie, MG .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10) :S283-S283
[6]  
Busby RW, 2005, GASTROENTEROLOGY, V128, pA464
[7]   Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans [J].
Coulie, B ;
Szarka, LA ;
Camilleri, M ;
Burton, DD ;
McKinzie, S ;
Stambler, N ;
Cedarbaum, JM .
GASTROENTEROLOGY, 2000, 119 (01) :41-50
[8]   GUANYLIN - AN ENDOGENOUS ACTIVATOR OF INTESTINAL GUANYLATE-CYCLASE [J].
CURRIE, MG ;
FOK, KF ;
KATO, J ;
MOORE, RJ ;
HAMRA, FK ;
DUFFIN, KL ;
SMITH, CE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (03) :947-951
[9]   Effects of single dose administration of MD-1100 on safety, tolerability, exposure, and stool consistency in healthy subjects [J].
Currie, MG ;
Kurtz, C ;
Mahajan-Miklos, S ;
Busby, RW ;
Fretzen, A ;
Geis, S .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09) :S328-S328
[10]  
*FDA PUBL HLTH ADV, 2007, TEG MAL